Dr. Dost Ongur, MD, PhD
Claim this profileMcLean Hospital
Studies Schizophrenia
Studies Psychosis Prodrome
4 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Dost Ongur, MD, PhD is currently running
Enhanced Care
for Psychosis
The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The main question it aims to answer is: • Does the addition of certain elements of care increase the number of visits in treatment for first-episode psychosis? Participants will either: * Receive care as usual (CSC) or * Receive care as usual (CSC) plus five additional care elements (CSC 2.0): 1. Individual peer support 2. Digital outreach 3. Care coordination 4. Multi-family group therapy 5. Cognitive remediation Researchers will compare the standard of care (CSC) to CSC 2.0 to see if participants receiving CSC 2.0 have more visits to their clinic in their first year.
Recruiting1 award N/A6 criteria
MitoQ
for Schizophrenia
The goal of this double-blind, placebo-controlled randomized clinical trial is to test the effect of 12 weeks of orally administered MitoQ (mitoquinol mesylate) supplementation on cognition in 50 people with early phase schizophrenia-spectrum disorders (E-SSD) who have mitochondrial dysfunction (called high risk, or HR). Cognitive impairments in SSD can cause significant disability. Yet, there are no effective treatments for cognitive impairments in SSD. It has been shown that alterations in a certain type of brain cell (parvalbumin interneurons, or PVI) underlie cognitive deficits in SSD. These PVI, which fire at a fast rate, utilize high amounts of energy from the mitochondria and are highly vulnerable to oxidative stress. MitoQ is an antioxidant. Research has shown that, in mice, MitoQ can reduce oxidative stress in the mitochondria. The main question that this clinical trial aims to answer is: • Does MitoQ supplementation, compared to placebo, improve cognition in HR patients? Secondary questions that this clinical trial aims to answer are the following: Does MitoQ supplementation, compared to placebo: * Improve positive and negative symptoms of SSD in HR patients? * Improve functioning in HR patients? * Improve/normalize blood markers of mitochondrial dysfunction in HR patients? The investigators will enroll 100 individuals with E-SSD. These enrolled participants will participate in an initial screening visit to determine if they qualify for the actual clinical trial. At the screening visit, the investigators will ask about psychiatric history to determine diagnosis; ask about medical history; do a physical exam; collect blood and urine samples; do a pregnancy test; and ask participants to bring in their current medications in their original packaging so it is known what they are taking. After the screening visit, the investigators will invite 50 HR patients (identified with a blood test) to continue with the clinical trial. Participants who qualify for the clinical trial will be asked to: * Take a supplement (MitoQ or placebo) once per day for 12 weeks in addition to their usual medications. * Come in for a study visit every 4 weeks over the 16-week study period. At these study visits, the investigators will do a physical exam; ask about symptoms and side effects; take blood and urine samples; and ask questions about general health and well-being, quality of life, mental health, emotional health, and mood. At visits 1 (baseline) and 4 (12 weeks), participants will also take a cognitive assessment.
Recruiting0 awards Phase 2 & 3
More about Dost Ongur, MD, PhD
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Dost Ongur, MD, PhD has experience with
- Enhanced Coordinated Specialty Care
- MitoQ
- Placebo
- Nicotinamide Riboside
- Intranasal Insulin
Breakdown of trials Dost Ongur, MD, PhD has run
Schizophrenia
Psychosis Prodrome
Mental Disorders
Psychosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dost Ongur, MD, PhD specialize in?
Dost Ongur, MD, PhD focuses on Schizophrenia and Psychosis Prodrome. In particular, much of their work with Schizophrenia has involved treating patients, or patients who are undergoing treatment.
Is Dost Ongur, MD, PhD currently recruiting for clinical trials?
Yes, Dost Ongur, MD, PhD is currently recruiting for 2 clinical trials in Belmont Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Dost Ongur, MD, PhD has studied deeply?
Yes, Dost Ongur, MD, PhD has studied treatments such as Enhanced Coordinated Specialty Care, MitoQ, Placebo.
What is the best way to schedule an appointment with Dost Ongur, MD, PhD?
Apply for one of the trials that Dost Ongur, MD, PhD is conducting.
What is the office address of Dost Ongur, MD, PhD?
The office of Dost Ongur, MD, PhD is located at: McLean Hospital, Belmont, Massachusetts 02478 United States. This is the address for their practice at the McLean Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.